From professional translators, enterprises, web pages and freely available translation repositories.
laropiprant
laropiprants
Last Update: 2017-04-26
Usage Frequency: 5
Quality:
laropiprant there are no data from the use of laropiprant in pregnant women.
laropiprants nav datu par laropipranta lietošanu grūtniecēm.
Last Update: 2012-04-10
Usage Frequency: 1
Quality:
laropiprant it is unknown whether laropiprant is excreted in human breast milk.
laropiprants nav zināms vai laropiprants izdalās mātes pienā cilvēkam.
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
effects of laropiprant on other medicinal products
laropipranta ietekme uz citām zālēm
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
laropiprant crosses the placenta in rats and rabbits.
laropiprants šķērso placentāro barjeru žurkām un trušiem.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
laropiprant is a potent and selective antagonist of dp1.
laropiprants ir spēcīgs un selektīvs dp1 antagonists.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
therefore, laropiprant is not an inducer or inhibitor of cyp3a4.
tādēļ laropiprants nav cyp3a4 induktors vai inhibitors.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
laropiprant blocks the receptors to which pgd2 normally attaches.
laropiprants bloķē receptorus, pie kā pgd2 parasti piesaistās.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
age had no clinically meaningful effect on the pharmacokinetics of laropiprant.
pacienta vecums laropipranta farmakokinētiku klīniski nozīmīgi neietekmē.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
gender had no clinically meaningful effect on the pharmacokinetics of laropiprant.
dzimums laropipranta farmakokinētiku klīniski nozīmīgi neietekmē.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
laropiprant suppresses pgd2 mediated flushing associated with administration of nicotinic acid.
laropiprants nomāc pgd2 mediēto pietvīkumu, ko izraisa nikotīnskābes lietošana.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
what pelzont contains • the active substances are nicotinic acid and laropiprant.
• aktīvās vielas ir nikotīnskābe un laropiprants.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
the two active substances in pelzont, nicotinic acid and laropiprant, have different modes of action.
divām pelzont aktīvajām vielām - nikotīnskābei un laropiprantam - ir atšķirīgs darbības mehānisms.
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
adding laropiprant to nicotinic acid reduced the symptoms of flushing caused by nicotinic acid.
laropipranta pievienošana nikotīnskābei samazināja nikotīnskābes izraisītos sarkšanas simptomus.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
pelzont 1,000 mg/20 mg modified-release tablets nicotinic acid/laropiprant
pelzont 1000 mg/20 mg ilgstošās darbības tabletes nicotinic acid/laropiprant
Last Update: 2017-04-26
Usage Frequency: 4
Quality:
in in vitro studies, laropiprant did not inhibit cyp1a2, cyp2b6, cyp2c19, cyp2d6, or cyp2e1-mediated reactions.
pētījumos in vitro laropiprants neinhibēja cyp1a2, cyp2b6, cyp2c19, cyp2d6 vai cyp2e1 mediētās reakcijas.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
studies in animals have shown reproductive toxicity at high doses of laropiprant (see section 5.3).
pētījumi ar dzīvniekiem pierāda reproduktīvo toksicitāti, lietojot laropipranta lielās devās (skatīt apakšpunktu 5. 3).
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
studies in animals have shown foetal developmental toxicity at high doses of laropiprant (see section 5.3).
pētījumi ar dzīvniekiem pierāda toksicitāti uz augļa attīstību, lietojot laropipranta lielās devās (skatīt 5.3 apakšpunktā).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the starting dose is one modified-release tablet (1,000 mg nicotinic acid/20 mg laropiprant) once a day.
sākuma deva ir viena ilgstošās darbības tablete (1000 mg nikotīnskābes/20 mg laropipranta) dienā.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
